evipedia.aidev
← Back

Laser Resurfacing for Skin Rejuvenation

Evidence Review created on 08/02/2026 using AI4L / Opus 5

Also known as: Laser Skin Resurfacing, Ablative Laser Resurfacing, Non-Ablative Laser Resurfacing, Fractional Laser Resurfacing, Fractional Photothermolysis, Laser Peel, Lasabrasion

Motivation

Laser resurfacing uses focused beams of light to remove or heat the surface and deeper layers of skin under precise control. The injury is deliberate: as the skin repairs itself, it lays down fresh connective tissue and a new outer layer, softening lines, evening out color and smoothing texture. Because it acts on the structural material of the skin rather than its surface appearance, it sits apart from creams or injections.

The technique grew out of surgical lasers repurposed in the 1990s for sun-damaged faces. Early full-surface treatments produced striking results alongside long recoveries and lasting complications, pushing the field toward gentler versions treating only part of the surface. Both remain in use, and clinics disagree about which trade-off is worth making.

Skin is also where a lifetime of sun damage is easiest to see and measure, and the treatment is now being examined for whether it clears that damaged tissue rather than only its appearance. This review examines how much laser resurfacing changes aged skin, how long the change lasts, what it does to the tissue beneath and its later disease risk, what can go wrong, how risk varies by skin tone, and how reliable the research is.

Benefits - Risks - Protocol - Conclusion

This section collects high-level expert overviews of laser resurfacing that discuss the procedure, its mechanism, or its place among skin-rejuvenation options in substantial depth.

  • #355 – Skincare strategies, the science of facial aging, and cosmetic-intervention guidance – Tanuj Nakra, M.D. & Suzan Obagi, M.D. - Peter Attia

    A long-form conversation with an oculofacial plastic surgeon and a dermatologic surgeon that places resurfacing lasers within the broader architecture of facial aging, covering how depth of treatment maps to result and to recovery. It is unusually candid about which cosmetic interventions are oversold relative to their evidence.

  • Dr. Teo Soleymani: How to Improve & Protect Your Skin Health & Appearance - Andrew Huberman

    A dermatologic surgeon specializing in skin cancer discusses laser treatments alongside retinoids, photoprotection and phototherapy, including the proposition that resurfacing may reduce precancerous field damage. Useful for situating resurfacing as a skin-health intervention rather than a purely cosmetic one.

  • Skin, Hair and Nail Health - Williams et al.

    A referenced protocol document that describes ablative and fractional resurfacing in the context of the full range of options for photoaged skin, including topical and nutritional approaches. Its value here is the comparison between procedural and non-procedural routes to the same endpoints.

  • Current Laser Resurfacing Technologies: A Review that Delves Beneath the Surface - Preissig et al., 2012

    A narrative review that lays out the physics of each laser class — wavelength, water absorption, ablation versus coagulation — and connects those parameters directly to clinical depth of effect and recovery time. It remains the clearest available primer on why different devices produce different results.

  • Laser Resurfacing for Aging Skin - American Society for Dermatologic Surgery

    A practitioner-society overview giving concrete procedural expectations: wound care schedule, swelling and peeling timelines, and healing duration. Conflict of interest: the American Society for Dermatologic Surgery is a membership organization whose members derive direct revenue from performing the procedures it describes, and its patient-facing material both explains and markets those procedures.

Note on priority experts: no relevant content on laser resurfacing was found on foundmyfitness.com (Rhonda Patrick) or chriskresser.com (Chris Kresser). Site searches on both platforms return material on red-light therapy, photobiomodulation, collagen supplementation and nutritional approaches to skin aging, but nothing addressing ablative or fractional resurfacing lasers. Both are therefore absent from the list above.

Grokipedia

  • Laser Skin Resurfacing

    The article gives a structured overview of ablative and non-ablative device classes, indications, and the procedural sequence, with an emphasis on how treatment depth drives both efficacy and complication rates. It is a useful orientation to terminology before reading the primary literature.

Examine

No Examine article exists for laser resurfacing. Examine’s coverage is limited to supplements, nutrition and dietary interventions, and it does not maintain intervention pages for energy-based procedures; the closest entries are red light therapy and low-level laser therapy, which are distinct interventions with different mechanisms and endpoints.

ConsumerLab

No ConsumerLab article exists for laser resurfacing. ConsumerLab’s remit is independent laboratory testing of supplements and consumer health products, so it does not review procedures or energy-based devices.

Systematic Reviews

This section lists the systematic reviews and meta-analyses that pool controlled evidence on laser resurfacing for skin rejuvenation.

Mechanism of Action

Laser resurfacing works by depositing optical energy into skin water with enough precision to destroy a defined depth of tissue while leaving adjacent tissue viable enough to repair it. The governing principle is selective photothermolysis: a wavelength is chosen whose absorption by the target — here, tissue water — is high enough that energy is confined to the target before it can diffuse into surrounding structures.

  • Wavelength and chromophore: Carbon dioxide (CO₂) lasers emit at 10,600 nm and erbium-doped yttrium aluminum garnet (Er:YAG) lasers at 2940 nm. Water absorbs the erbium wavelength roughly ten to sixteen times more strongly, so erbium removes tissue more cleanly with a thinner rim of residual heat, while carbon dioxide leaves a deeper coagulated zone. That residual heat is not purely a defect — it is the stimulus for much of the downstream collagen response.

  • The wound-healing cascade: Thermal injury denatures dermal collagen and triggers an inflammatory phase, followed by fibroblast recruitment and a proliferative phase. Heat shock proteins (cellular chaperones that protect and refold damaged proteins), transforming growth factor beta 1 (TGF-β1, a signalling protein that drives scar and collagen formation) and matrix metalloproteinases (enzymes that break down and remodel the collagen scaffold) coordinate the sequence. Type I and type III procollagen deposition rises over weeks and continues remodelling for three to six months, which is why the visible result lags the procedure.

  • Fractional photothermolysis: The dominant modern approach, introduced by Manstein and colleagues in 2004, replaces confluent treatment of the whole surface with a grid of microscopic treatment zones (narrow columns of injured tissue) separated by untreated skin. Because intact keratinocytes and adnexal structures (hair follicles and sweat glands, which act as reservoirs of regenerative cells) survive between the columns, re-epithelialization takes days rather than weeks. Pigment and damaged material are extruded through the epidermis as microscopic epidermal necrotic debris.

  • Ablative versus non-ablative delivery: Ablative devices vaporise the epidermis; non-ablative devices such as the 1550 nm erbium-doped fiber laser and the 1927 nm thulium laser coagulate dermal columns while leaving the epidermis intact. The trade-off is direct: non-ablative treatment shortens recovery and reduces infection risk at the cost of a smaller per-session effect, requiring more sessions.

  • Competing mechanistic explanations: Two accounts of the visible result compete. The neocollagenesis account holds that measurable new collagen and dermal thickening produce a durable structural change. The alternative account holds that a substantial share of the early improvement reflects dermal oedema (fluid swelling), epidermal thickening and altered light scattering, all of which resolve — which would explain why photographic improvement at one month commonly exceeds improvement at twelve months. Histological studies confirm real collagen deposition, but the correlation between histological change and blinded clinical rating is weaker than the mechanistic story implies, and neither account has been decisively excluded.

  • No systemic pharmacology: Laser resurfacing is a device-delivered physical intervention, not a pharmacological compound. It has no half-life, no receptor selectivity, no tissue distribution beyond the treated field, and no hepatic or renal metabolism. Dose is expressed as fluence (energy per unit area), pulse duration, coverage density and number of passes rather than as milligrams.

Historical Context & Evolution

  • Original intended use: The carbon dioxide laser was developed at Bell Laboratories in 1964 and entered surgery in the 1970s as a bloodless cutting and ablating instrument. Its dermatological use was destructive rather than cosmetic: removal of warts, rhinophyma (bulbous overgrowth of the nose seen in advanced rosacea), actinic cheilitis (sun-induced precancerous change of the lip) and other lesions. Cosmetic resurfacing emerged as an observation from that work — clinicians noticed that skin healing after lesion removal was smoother and more evenly pigmented than the surrounding field.

  • The route to skin rejuvenation: The 1983 formulation of selective photothermolysis by Anderson and Parrish gave a physical basis for confining injury to a chosen depth. High-energy pulsed and rapidly scanned carbon dioxide systems reaching the market in the early 1990s made that control practical at whole-face scale, and full-field resurfacing displaced dermabrasion and deep phenol peeling for photoaged skin over roughly five years. Erbium-doped yttrium aluminum garnet systems followed from 1996 as a shorter-recovery alternative.

  • What the early research actually found: The full-field carbon dioxide literature of the mid-to-late 1990s documented the largest wrinkle reductions ever reported for a non-surgical facial procedure, with periorbital (around the eyes) and perioral (around the mouth) improvement sustained for years and histological confirmation of a new subepidermal band of collagen. The same literature documented the costs: erythema (redness) persisting a median of about four months, delayed hypopigmentation (lasting loss of skin pigment) in a substantial minority, and scarring where treatment strayed off the face. Both sets of findings came from the same body of work and neither has been retracted.

  • Why the field moved: Fractional photothermolysis in 2004 and ablative fractional devices from 2007 onward shifted practice decisively toward partial-coverage treatment. It is frequently stated that full-field ablative resurfacing was superseded because it was shown to be inferior. That claim does not survive contact with the comparative data: the pooled randomized evidence finds no significant efficacy advantage for ablative over non-ablative devices but rests on very small samples, while split-face comparisons continue to favour deeper carbon dioxide treatment on wrinkle endpoints. The migration was driven by downtime, liability exposure, the ability to treat darker skin, and a device market that could sell repeat sessions — considerations that are commercially and practically legitimate but are not efficacy findings.

  • Evolution of opinion, and what remains open: Current practice treats fractional delivery as the default and reserves full-field ablation for severe photoaging in fair skin. What changed to produce that position was tolerability and market structure more than head-to-head outcome data; what has not changed is the absence of adequately powered, long-duration randomized comparisons between the two. Recent development has moved toward 2910 nm erbium-doped fluoride fiber lasers, hybrid devices combining ablative and non-ablative wavelengths in a single pass, and laser-assisted delivery of topical agents through the treatment columns. Whether these represent genuine gains or incremental repackaging is not yet settled by independent evidence.

Expected Benefits

Benefits below are graded for a reader who is willing to accept a defined recovery period and out-of-pocket cost in exchange for a measurable structural change, and who will maintain photoprotection afterwards. That framing matters: several of these benefits degrade quickly without sustained sun avoidance, and the published averages include participants who did not maintain it.

High 🟩 🟩 🟩

Reduction of Facial Wrinkles and Fine Lines ⚠️ Conflicted

The best-established effect. Ablative resurfacing softens fine and moderate rhytides (wrinkles), with the largest effect in the periorbital and perioral regions where the skin is thin and the deposited energy reaches proportionally deeper. Split-face controlled studies pooled by Chen and colleagues found carbon dioxide lasers more effective than erbium lasers on wrinkle scores, with erbium showing the better complication profile. The size of the advantage held by deeper ablative treatment is directly conflicted: split-face comparisons continue to favour it on wrinkle endpoints, while the pooled randomized evidence comparing ablative with non-ablative devices found no significant difference in the odds of excellent improvement — a null result (no difference found) resting on only 124 pooled participants, so the discrepancy may reflect statistical power (the ability to detect a real difference, which falls with small samples) and outcome scale rather than a genuine absence of difference. The evidence rests on investigator-rated ordinal scales rather than instrumented measurement, which inflates apparent precision, and deep static folds caused by volume loss rather than surface change do not respond.

Magnitude: Roughly 40–60% mean improvement in graded wrinkle scores after a single full-field ablative treatment; approximately 20–40% after a course of three to five fractional sessions.

Resurfacing removes or disperses accumulated epidermal melanin and replaces the disorganised, sun-damaged outer layer, improving mottled pigmentation, solar lentigines (flat brown sun spots) and surface roughness. The mechanism is direct removal plus melanin extrusion through the treatment columns, rather than pigment-cell suppression, which is why the result is durable when sun exposure is controlled and reverses when it is not. The evidence basis is pooled meta-analysis of randomized and split-face comparative trials across every device class, and this is the endpoint on which those classes agree most closely, with non-ablative fractional devices performing nearly as well as ablative ones.

Magnitude: Typically 50–75% clearance of discrete solar lentigines and one to two grades of improvement on photoaging classification scales.

Improvement of Atrophic Acne Scars

Atrophic (depressed) acne scarring responds to fractional resurfacing through the same collagen-remodelling pathway that addresses photoaging, with the treatment columns targeting the tethered scar base. Multiple controlled trials and pooled analyses support fractional carbon dioxide treatment here, and it is one of the few resurfacing indications with an economic evaluation attached. Boxcar and rolling scars respond substantially better than narrow ice-pick scars, which often require adjunctive techniques.

Magnitude: Approximately 25–50% mean reduction in scar severity scores after three to five fractional sessions, with greater response in rolling and boxcar morphologies.

Medium 🟩 🟩

Dermal Collagen Remodeling and Increased Dermal Thickness

Biopsy studies after both ablative and fractional treatment show a new band of organised type I and type III collagen beneath the epidermis, increased dermal thickness, and reorganisation of degraded elastic fibres. This is a structural change rather than a cosmetic one, and it is the strongest argument that resurfacing does something categorically different from topical agents. The evidence base is histological and mechanistic, from small biopsy series rather than powered trials, and the correlation between measured collagen change and blinded clinical improvement is only moderate.

Magnitude: Reported dermal thickness increases of roughly 10–30% at three to six months, with new collagen deposition detectable for at least six months post-treatment.

Clearance of Actinic Keratoses and Precancerous Field Damage

Actinic keratoses (rough, scaly precancerous patches caused by cumulative sun exposure) can be cleared by ablative resurfacing, which removes the damaged epidermal field rather than individual lesions. Ablative fractional resurfacing is also used to improve the penetration of photosensitising agents in photodynamic therapy, and combined laser-plus-photodynamic protocols have controlled evidence supporting them. Laser monotherapy for this indication has weaker support than the combined approach, and recurrence within the treated field is common because the underlying genetic damage in surviving cells is unaffected.

Magnitude: Reported short-term clearance rates of roughly 70–90% for treated actinic keratoses, with substantial recurrence within one to two years.

Enhanced Delivery of Topical Actives

The microscopic channels created by ablative fractional treatment bypass the stratum corneum (the barrier layer that normally limits topical absorption), raising delivery of applied compounds by orders of magnitude. This underlies laser-assisted drug delivery protocols pairing resurfacing with vitamin C, growth factors, or corticosteroids, and it has clinical practice guidelines devoted to it. The efficacy evidence is strongest for scar and precancer indications; for cosmetic rejuvenation specifically, the added benefit over resurfacing alone is less clearly demonstrated, and the same channels raise the risk of adverse reaction to whatever is applied.

Magnitude: Increases in transcutaneous delivery of applied compounds of roughly 10-fold to 100-fold depending on molecular size and channel depth.

Low 🟩

Skin Tightening and Laxity Improvement ⚠️ Conflicted

Some contraction of the treated field occurs through immediate collagen denaturation and subsequent fibrosis, and practitioners consistently report modest tightening after deep ablative treatment. The evidence is genuinely conflicted: pooled comparative work finds radiofrequency and microfocused ultrasound performing at least as well on laxity endpoints, some controlled trials find no measurable tightening beyond the oedema phase, and the effect is not separable from the wrinkle-reduction endpoint in most study designs. Laxity driven by loss of deep facial fat and ligamentous descent is anatomically inaccessible to a resurfacing laser at any setting.

Magnitude: Modest, typically under 10% linear contraction of the treated field where reported, with several controlled studies finding no significant effect.

Improvement of Photoaged Skin on the Hands, Neck and Chest

Non-facial photoaged skin can be treated, and controlled work includes hand rejuvenation endpoints. Response is real but smaller than on the face, because these sites have fewer hair follicles and sweat glands to repopulate the epidermis and therefore tolerate much lower treatment density. The evidence base is thin, largely uncontrolled, and the same anatomical constraint that limits efficacy also drives a disproportionate share of the scarring complications reported in the literature.

Magnitude: Roughly one grade of improvement on photoaging scales at conservative densities, with treatment settings typically reduced to a third or less of facial parameters.

Speculative 🟨

Long-Term Reduction in Keratinocyte Carcinoma Incidence

The hypothesis is that removing or resetting sun-damaged epidermal fields lowers the subsequent rate of basal cell and squamous cell carcinoma. It is mechanistically coherent — preclinical work shows ablative fractional treatment altering tumour-driving gene expression in animal models — and is actively advocated by some dermatologic surgeons. The human evidence amounts to two small controlled trials in heavily photodamaged patients plus a retrospective cohort, all drawn from populations already under intensive skin-cancer surveillance; no randomized trial has used cancer incidence as a prespecified endpoint, so any effect in someone treated for rejuvenation alone remains an extrapolation from mechanism and from a narrow secondary-prevention setting.

Reduction of Local Senescent Cell Burden

Photoaged skin accumulates senescent fibroblasts that secrete inflammatory mediators and degrade the dermal matrix, and controlled wounding plausibly clears some of that population while repopulating the dermis with younger fibroblasts. This would make resurfacing a local intervention against a recognised aging mechanism rather than a cosmetic one. No human study has measured senescent cell burden before and after resurfacing; the basis is entirely mechanistic extrapolation from wound-healing and cellular-senescence biology.

Benefit-Modifying Factors

  • Genetic pigmentation variants: Variants in the melanocortin 1 receptor gene (MC1R, which determines whether melanocytes produce dark eumelanin or red-yellow pheomelanin) and related pigmentation loci track with Fitzpatrick skin phototype (a I–VI classification of how skin responds to sun exposure) and therefore with the treatment settings that can be used safely. Lighter phototypes tolerate higher fluences and denser coverage, which is the principal reason reported efficacy is higher in phototypes I–III.

  • Fibrotic-response variants: Polymorphisms affecting transforming growth factor beta 1 signalling and familial keloid tendency (an inherited predisposition to thick, raised scars that spread beyond the original wound) shift the healing response toward more collagen deposition. This modestly increases the remodelling benefit but simultaneously raises hypertrophic scarring risk, so the net effect on desirable outcome is not favourable in strong responders.

  • Baseline photoaging severity: The single strongest predictor of measured improvement is how damaged the skin was at baseline. Severely photoaged skin has more to gain and shows larger absolute score changes; skin already in good condition shows small absolute changes that are difficult to distinguish from measurement noise. Published mean improvements are therefore not transferable to someone with mild baseline damage.

  • Baseline biomarker status: Glycemic control, iron status, protein status and vitamin D status all influence re-epithelialization speed and collagen synthesis. Elevated hemoglobin A1c (a measure of average blood sugar over roughly three months) is associated with slower and more disordered wound healing; iron is a required cofactor for the enzymes that stabilise collagen; and low serum albumin signals insufficient substrate for matrix synthesis.

  • Sex-based differences: Male facial skin is thicker with a denser dermal collagen network, more terminal hair follicles and richer vascular supply. The higher follicular density supports faster re-epithelialization and better tolerance of aggressive settings, while the thicker dermis means a given fluence penetrates proportionally less deeply, so men often need higher settings for equivalent wrinkle improvement. Women show larger measured improvements in perioral rhytides, partly because perioral photoaging is more prevalent and more severe in women.

  • Pre-existing health conditions: Diabetes, peripheral vascular disease, active smoking, connective tissue disease and immunosuppression all impair the healing response the benefit depends on. Prior rhytidectomy (facelift) alters cutaneous blood supply in the undermined field, and prior radiotherapy to the treatment area destroys the adnexal reservoirs that repopulate the epidermis, sharply reducing achievable benefit.

  • Age-related considerations: Older skin has fewer and less proliferative fibroblasts, thinner dermis and slower re-epithelialization, so the collagen response to a given dose is smaller and slower. This does not eliminate benefit — severely photoaged older skin often shows the largest absolute improvement because baseline damage is greatest — but it lengthens the interval to visible result, commonly six months rather than three, and argues for staged lower-energy sessions past roughly age 70.

Potential Risks & Side Effects

Risks below are framed for someone who will select an experienced operator, follow a prophylaxis and aftercare protocol, and can schedule genuine recovery time. Under those conditions the absolute risk of the serious outcomes is materially lower than the published averages, which include treatments delivered in less controlled settings.

High 🟥 🟥 🟥

Post-Procedure Erythema

Erythema (persistent redness of the treated skin) follows every effective resurfacing treatment and is a direct consequence of the inflammatory and revascularisation phases of healing, not a complication. Its duration scales with treatment depth: days to two weeks after non-ablative fractional treatment, several weeks after ablative fractional treatment, and historically a median of about four months after full-field carbon dioxide resurfacing. Pooled trial data show combination protocols producing shorter erythema than single-device treatment. It is fully reversible but is the adverse effect most likely to interfere with normal activity.

Magnitude: Near-universal; mean duration approximately 12.8 days for combination protocols versus 15.2 days for single-device laser monotherapy, extending to a median of roughly four months after full-field ablative treatment.

Post-Inflammatory Hyperpigmentation ⚠️ Conflicted

Post-inflammatory hyperpigmentation is transient darkening of the treated skin caused by inflammation-driven melanin production and transfer. It is the dominant risk in darker skin: reported incidence rises steeply with Fitzpatrick phototype, treatment density and total delivered energy, and is consistently higher with ablative than with non-ablative settings in phototype-stratified series. The direction of that ablative-versus-non-ablative gradient is itself conflicted: the largest pooled safety dataset reported fewer adverse events overall after ablative treatment than after non-ablative treatment, the reverse of what the phototype-stratified series show, a discrepancy most plausibly explained by case mix, since deeper treatment is preferentially offered to lighter phototypes in whom pigmentary reaction is uncommon. The evidence basis is phototype-stratified device case series and pooled safety reviews rather than randomized comparison, which is why the reported rates vary widely between series and settings. It resolves over weeks to months with photoprotection and topical pigment suppression but can persist for a year, and it is the reason phototype-stratified settings and pre-treatment are standard.

Magnitude: Roughly 5–15% with non-ablative fractional devices in phototypes IV–VI; commonly reported in the 20–40% range after ablative treatment in the same phototypes and under 5% in phototypes I–II.

Procedural Pain and Discomfort

Ablative resurfacing is painful, requiring topical anaesthetic, regional nerve blocks, or sedation depending on depth and field size, with a burning sensation persisting for 12–72 hours afterwards. Pooled trial data quantify this: mean pain scores of about 7.2 out of 10 for single-device laser treatment versus 4.8 for combination protocols. The pain is short-lived and pharmacologically manageable, but the requirement for sedation in deeper treatments introduces its own risk profile, and compounded high-concentration topical anaesthetics applied over large areas have caused systemic lidocaine toxicity.

Magnitude: Mean intra-procedural pain approximately 7.2/10 for laser monotherapy and 4.8/10 for combination protocols; post-procedural stinging typically 12–72 hours.

Oedema, Crusting and Functional Downtime

Oedema (fluid swelling) peaks in the first 24–48 hours, followed by serous oozing, crusting and sloughing of the treated epidermis at days five to seven. Full re-epithelialization takes approximately 10–21 days after ablative treatment depending on field size and depth, during which the skin is an open wound requiring cleansing four to five times daily and continuous occlusive ointment. The evidence basis is ablative resurfacing cohort series and device wound-care protocols rather than randomized comparison, so these are typical rather than bounded ranges. This is an expected consequence of the mechanism rather than a complication, but it is routinely underestimated and is the most common source of post-procedure regret.

Magnitude: Swelling 24–48 hours; peeling at days 5–7; complete healing typically 10–21 days after ablative treatment and 3–7 days after non-ablative fractional treatment.

Medium 🟥 🟥

Delayed Permanent Hypopigmentation

Permanent loss of pigment in the treated field — historically described as “alabaster skin” — appears six to twelve months after treatment, long after apparent healing, and reflects destruction or permanent dysfunction of melanocytes at the depth of injury. It is the most consequential complication of full-field ablative resurfacing because it is untreatable and produces a visible demarcation line at the treatment border. The evidence basis is long-term follow-up of full-field carbon dioxide cohorts from the 1990s together with later fractional-device case series; no randomized trial has tracked pigment outcomes far enough out to capture it. Fractional delivery reduced its incidence by orders of magnitude by sparing untreated skin between columns, which is the single clearest safety gain of the fractional era.

Magnitude: Historically reported in roughly 10–20% of full-field carbon dioxide resurfacing cases at 6–12 months; well under 1% with fractional devices.

Infection and Herpes Simplex Reactivation

The resurfaced field is a large open wound without an intact barrier, permitting bacterial infection, candidal overgrowth (yeast infection of the treated skin) and — most characteristically — reactivation of latent herpes simplex virus (the virus responsible for cold sores). Disseminated herpetic infection across a resurfaced face can cause scarring and is a genuine emergency. The evidence sits at medium rather than high because the reported reactivation rates come from single-centre case series and uncontrolled cohorts rather than from controlled trials, and the figures with and without antiviral prophylaxis differ by an order of magnitude across those series.

Magnitude: Herpes simplex reactivation reported in roughly 2–7% with prophylaxis and in excess of 40% without it in seropositive individuals; bacterial or candidal infection in approximately 1–4%.

Hypertrophic Scarring

Raised, firm scarring occurs when injury extends below the reticular dermis or when re-epithelialization is delayed by infection or poor aftercare. It concentrates at anatomical sites with sparse adnexal structures — the neck, chest, jawline and periorbital margin — and in individuals with keloid tendency or recent exposure to isotretinoin (an oral retinoid for severe acne). In the largest pooled safety dataset, hypertrophic scarring occurred in five of 1093 patients. It is partially treatable with intralesional corticosteroids, silicone and vascular laser, but complete resolution is not assured.

Magnitude: Approximately 0.5% (5 of 1093 patients) in pooled systematic review data, with substantially higher rates for off-face treatment sites.

Acneiform Eruption and Milia

Occlusive ointments applied continuously during healing, combined with a regenerating follicular epithelium, commonly provoke acneiform papules and milia (small white keratin cysts) in the second and third weeks. The mechanism is follicular occlusion plus altered keratinisation in newly formed epidermis, and the evidence basis is adverse-event tallies in resurfacing case series rather than controlled trials, which is why reported rates vary widely with the aftercare regimen used. It is self-limiting and responds to switching to a lighter emollient and, where needed, topical treatment, but it is distressing because it appears just as the skin is expected to be improving.

Magnitude: Reported in roughly 10–20% of ablative resurfacing cases, typically resolving within four to six weeks.

Low 🟥

Ectropion and Periorbital Complications

Ectropion (outward turning of the lower eyelid margin, exposing the inner surface) can follow aggressive periorbital treatment through skin contraction in a region with minimal tissue reserve, and is most likely in those with pre-existing eyelid laxity or prior lower blepharoplasty (eyelid surgery). The evidence basis is periorbital resurfacing case series and oculoplastic complication reports rather than controlled trials, and it is graded low because it is uncommon and largely avoidable through pre-treatment eyelid-laxity assessment and reduced periorbital settings, though correction requires surgery. Corneal injury from inadequate eye shielding is a separate and preventable periorbital hazard.

Magnitude: Uncommon; reported in well under 1% of periorbital resurfacing procedures, concentrated in those with pre-existing lid laxity or prior eyelid surgery.

Allergic and Irritant Contact Dermatitis

The barrier-disrupted healing field absorbs topical agents far more readily than intact skin, so sensitisation to post-procedure products is disproportionately common. Neomycin, bacitracin, fragranced emollients and botanical extracts are frequent culprits, and the resulting dermatitis prolongs erythema and can be mistaken for infection. The evidence basis is patch-testing studies of the implicated agents plus case series of post-resurfacing dermatitis; no controlled trial has compared aftercare regimens for this endpoint. Preventable by restricting aftercare to plain petrolatum and bland cleansers during re-epithelialization.

Magnitude: Reported in roughly 1–5% of ablative resurfacing cases when topical antibiotics are used, and considerably lower with petrolatum-only protocols.

Prolonged Photosensitivity and Rebound Pigmentation

Newly re-epithelialized skin lacks a mature stratum corneum and has an altered melanocyte population, leaving it unusually vulnerable to ultraviolet exposure for months. Sun exposure during this window causes disproportionate pigment darkening that can undo the dyspigmentation benefit entirely. The evidence basis is barrier-recovery measurement studies and clinical follow-up series reporting pigment relapse in sun-exposed patients rather than randomized data. The mechanism is straightforward barrier and pigment immaturity; the risk is behavioural rather than procedural and is fully controllable.

Magnitude: Heightened ultraviolet sensitivity for approximately 3–6 months post-treatment; sun exposure in this window is the leading cause of loss of pigmentary benefit.

Speculative 🟨

Cumulative Dermal Atrophy from Repeated Aggressive Treatment

Repeated deep treatment could in principle deplete fibroblast populations and adnexal reservoirs faster than they regenerate, producing thinner, more fragile skin over decades rather than thicker skin. No longitudinal study has followed individuals through many treatment cycles with dermal measurement, and the concern rests on general wound-healing and replicative-senescence biology plus isolated clinical reports of atrophy after aggressive repeated treatment. It remains an unmeasured possibility rather than a documented outcome.

Koebnerization of Latent Inflammatory Skin Disease

Controlled cutaneous injury can trigger lesions of psoriasis, vitiligo (patchy loss of skin pigment) or lichen planus (an itchy, purplish inflammatory rash) in the injured field in predisposed individuals, a phenomenon known as koebnerization (the appearance of an existing skin disease at the site of trauma). Case reports of vitiligo and psoriasis appearing in resurfaced fields exist but there is no controlled incidence data and no way to quantify baseline predisposition; the basis here is mechanistic and from isolated reports only.

Risk-Modifying Factors

  • Genetic pigmentation and fibrosis variants: Melanocortin 1 receptor and related pigmentation genotypes underlie Fitzpatrick phototype and therefore the dominant risk gradient for post-inflammatory hyperpigmentation. Separately, familial keloid predisposition and variants amplifying transforming growth factor beta 1 signalling raise hypertrophic scarring risk, and a personal or family history of keloids is the single most useful proxy for these in the absence of testing.

  • Baseline biomarker status: Elevated hemoglobin A1c, low serum albumin, low ferritin and low 25-hydroxyvitamin D each predict slower re-epithelialization, and delayed re-epithelialization is the proximate driver of both scarring and infection. Elevated high-sensitivity C-reactive protein (a sensitive marker of systemic inflammation) signals a pro-inflammatory baseline associated with more prolonged post-procedure erythema.

  • Sex-based differences: Men have higher follicular density and faster re-epithelialization, which lowers scarring and infection risk, but also more vascular skin with greater intra-procedural bleeding and more prolonged erythema. Women have a higher incidence of melasma (patchy facial pigmentation strongly influenced by hormones), which markedly raises the risk of post-inflammatory hyperpigmentation and can be worsened rather than improved by resurfacing; pregnancy and combined oral contraceptive use amplify this.

  • Pre-existing health conditions: Poorly controlled diabetes, active smoking, immunosuppressive therapy, connective tissue disease such as scleroderma (progressive hardening and thickening of the skin) or lupus, and active infection all raise complication risk. Prior radiotherapy to the field and prior facelift undermining both compromise the healing reserve. A history of herpes labialis (recurrent cold sores on or around the lips) converts infection from a low to a high probability event without prophylaxis, and isotretinoin exposure within six months is the classic scarring risk factor.

  • Age-related considerations: Slower re-epithelialization with age extends the window of barrier compromise and therefore the exposure to infection and scarring, and thinner dermis means a given fluence reaches proportionally closer to the subcutaneous layer. Beyond roughly age 70, reduced adnexal density is the limiting factor, and conservative density with staged sessions is the standard risk adaptation. Concurrent anticoagulant and antiplatelet use (medicines that slow clotting or stop platelets clumping together), which is more prevalent with age, adds bleeding risk and purpura (purple-red patches of bleeding under the skin).

Key Interactions & Contraindications

  • Isotretinoin: Severity — relative contraindication for ablative treatment. Isotretinoin suppresses sebaceous gland activity, and sebaceous glands contribute to re-epithelialization, so exposure raises atypical scarring risk. Mitigation: a washout of six months before ablative resurfacing is the long-standing convention, although a 2017 practitioner-society consensus concluded the evidence does not support delay for superficial and fractional procedures — a conclusion issued by a body whose membership derives direct revenue from performing the procedures it thereby makes available to more patients.

  • Anticoagulants and antiplatelet agents (warfarin, apixaban, rivaroxaban, clopidogrel, aspirin): Severity — caution. Clinical consequence: increased intra-procedural bleeding, prolonged oozing and post-procedure purpura. Mitigation: elective discontinuation is undertaken only in consultation with the prescribing clinician, and anticoagulation is not interrupted for a cosmetic procedure where the underlying indication is thrombotic.

  • Over-the-counter analgesics and antiplatelet agents (aspirin, ibuprofen, naproxen, diclofenac gel): Severity — caution. Clinical consequence: platelet inhibition raises intra-procedural bleeding, prolonged oozing and post-procedure purpura, and the same agents are frequently taken without being reported as medication. Mitigation: practitioner protocols withhold non-essential over-the-counter non-steroidal anti-inflammatory drugs (medicines such as ibuprofen that reduce pain and inflammation) for roughly 10 days before ablative treatment, with paracetamol used for analgesia instead; low-dose aspirin taken for cardiovascular indications is treated as prescribed therapy and is not withheld without the prescribing clinician.

  • Over-the-counter topical actives (retinol and retinaldehyde, alpha- and beta-hydroxy acid exfoliants, benzoyl peroxide, hydroquinone, physical scrubs): Severity — caution, timing separation. Clinical consequence: a pre-thinned or already irritated stratum corneum increases the effective depth of a given fluence and prolongs erythema, and reintroducing them onto unhealed skin provokes irritant dermatitis. Mitigation: standard protocols stop these products five to seven days before treatment and reintroduce them only after re-epithelialization is complete, apart from pigment-suppressing pre-treatment that is deliberately prescribed and timed.

  • Photosensitizing medications (doxycycline, minocycline, ciprofloxacin, hydrochlorothiazide, amiodarone, voriconazole): Severity — caution, timing separation. Clinical consequence: exaggerated post-procedure erythema and pigmentary change on incidental ultraviolet exposure during the vulnerable healing window. Mitigation: substitution or a pause is arranged where clinically permissible, and strict photoprotection is maintained for three to six months.

  • Immunosuppressants (prednisone, tacrolimus, mycophenolate, methotrexate, tumour necrosis factor inhibitors — biologic drugs that block a central inflammatory signal): Severity — caution to relative contraindication depending on degree of suppression. Clinical consequence: impaired re-epithelialization, higher bacterial and herpetic infection risk, delayed collagen deposition. Mitigation: extended antiviral and antibacterial prophylaxis, reduced treatment density, and coordination with the prescribing specialist.

  • Supplements with antiplatelet or anticoagulant effects (fish oil, high-dose vitamin E, Ginkgo biloba, garlic, ginger, Panax ginseng, nattokinase, curcumin): Severity — caution; these are additive with pharmaceutical anticoagulants and with each other. Clinical consequence: increased bruising, bleeding and prolonged oozing. Mitigation: protocols discontinue these 10–14 days before the procedure and resume them once re-epithelialization is complete.

  • Photosensitizing supplements (St. John’s wort, bergamot and other citrus-derived botanical extracts, Ammi majus and Angelica preparations): Severity — caution. Clinical consequence: these carry furocoumarins (plant compounds that make skin react far more strongly to ultraviolet light), amplifying ultraviolet reactivity in newly healed skin. Mitigation: a pause of two weeks before the procedure and through the healing window is the usual arrangement.

  • Supplements supporting the same healing pathway (vitamin C, zinc, arginine, hydrolysed collagen peptides, bromelain): Severity — generally favourable additive effect rather than a hazard. Clinical consequence: these act on the same collagen synthesis and inflammation-resolution pathways the procedure depends on. Mitigation: none required; zinc above 40 mg daily for extended periods risks copper depletion, so protocols keep intakes at that level time-limited.

  • Other cosmetic interventions: Severity — caution, timing separation. Botulinum toxin injected into the treatment field within two weeks may diffuse unpredictably in oedematous tissue; hyaluronic acid fillers placed superficially can be degraded by heat; chemical peels, microneedling and radiofrequency in the same field within four to six weeks compound the injury. Mitigation: injectable procedures are separated by two weeks before and four weeks after, and other resurfacing procedures by at least six weeks. Concurrent resurfacing during facelift surgery is performed by some surgeons and carries a distinct flap-perfusion risk profile.

  • Populations who should avoid this intervention: Absolute or near-absolute exclusions include active herpes labialis or bacterial infection in the field; isotretinoin exposure within six months for ablative treatment; prior radiotherapy to the treatment field; active connective tissue disease with cutaneous involvement (systemic sclerosis, cutaneous lupus); a history of keloid formation; pregnancy and lactation (on the basis of absent safety data and elevated melasma risk rather than demonstrated harm); and unrealistic expectations of correcting volume-loss laxity. Full-field ablative treatment is contraindicated in Fitzpatrick phototypes IV–VI outside highly specialised settings. Relative exclusions include hemoglobin A1c above 8.0%, current smoking, active vitiligo or psoriasis, prior lower blepharoplasty with residual lid laxity (ectropion risk), and inability to commit to three to six months of strict photoprotection.

Risk Mitigation Strategies

  • Antiviral prophylaxis for every ablative treatment: Valaciclovir 500 mg twice daily beginning one day before the procedure and continuing 7–10 days until re-epithelialization is complete, extended to 1 g twice daily for full-field treatment. This converts herpes simplex reactivation — the complication most likely to cause scarring on an otherwise well-executed treatment — from a probable event to an uncommon one in seropositive individuals.

  • Phototype-stratified settings and pre-treatment: In Fitzpatrick phototypes III and above, hydroquinone 4% with tretinoin 0.025–0.05% nightly for four to six weeks before treatment, then resumed once healed, together with reduced coverage density (typically 5–15% rather than 20–30%) and lower fluence. This directly targets post-inflammatory hyperpigmentation, the dominant adverse event in darker skin, which correlates with both delivered energy and treatment density.

  • Test spot before full-field treatment: A 1–2 cm test area treated at intended settings in a concealed location four to six weeks before the full procedure, in anyone at phototype IV or above or with a history of pigmentary reaction. Four to six weeks is required because post-inflammatory hyperpigmentation peaks well after healing; a shorter interval will miss it. This prevents committing a whole face to settings that produce a pigmentary complication.

  • Density reduction at low-adnexal sites: Coverage density reduced to roughly 5–10% and fluence to a third or less of facial parameters on the neck, chest, jawline and hands, with no stacked passes. These sites have sparse hair follicles and sweat glands and therefore little regenerative reserve; the majority of hypertrophic scarring reported in the resurfacing literature arises from applying facial parameters to them.

  • Strict photoprotection for three to six months: Broad-spectrum sun protection factor 30–50 applied daily, with physical shading and avoidance of direct midday exposure, beginning as soon as the skin tolerates topical application. This addresses both rebound hyperpigmentation and loss of the dyspigmentation benefit, which is the most common way an otherwise successful treatment is undone.

  • Petrolatum-only aftercare: Cleansing with plain water or a bland non-soap cleanser four to five times daily followed by plain petrolatum, avoiding neomycin, bacitracin, fragranced emollients and botanical products until fully re-epithelialized. This prevents allergic contact dermatitis, which is disproportionately common through a disrupted barrier and prolongs erythema while mimicking infection.

  • Isotretinoin washout and smoking cessation: Six months between the last isotretinoin dose and ablative resurfacing, and complete tobacco cessation for two weeks before and at least two weeks after. Both target impaired re-epithelialization — the shared upstream cause of atypical scarring, infection and prolonged erythema.

  • Metabolic optimisation before elective treatment: Hemoglobin A1c below 6.0%, serum albumin above 4.0 g/dL, ferritin above 50 ng/mL and 25-hydroxyvitamin D above 30 ng/mL corrected in advance where deficient, since each is rate-limiting for wound healing. Delaying an elective procedure by 8–12 weeks to correct these reduces the window of barrier compromise that drives infection and scarring risk.

  • Staged treatment rather than a single aggressive pass: Two to four moderate-energy fractional sessions at six- to eight-week intervals in place of one maximal-depth treatment, particularly past age 70 or where healing capacity is uncertain. Cumulative collagen response is comparable while the depth of injury at any one time — the determinant of scarring and permanent hypopigmentation risk — stays well below threshold.

  • Operator and setting selection: Treatment by a physician credentialled on the specific device, in a facility equipped for the anaesthesia depth used, with corneal shields for periorbital work and plume evacuation in place. Device-specific experience is the strongest determinant of complication rate in the reported literature, and delegation of ablative settings to unsupervised non-physician operators is permitted in many jurisdictions but is associated with the reported burn and scarring cases.

Therapeutic Protocol

  • Full-field ablative carbon dioxide resurfacing: The deepest standard approach, using a 10,600 nm pulsed or scanned system at roughly 250–350 mJ per pulse over two to three passes, with visible collagen contraction and char removal between passes. Popularised by the La Jolla group of Richard Fitzpatrick and Mitchel Goldman and by Tina Alster at the Washington Institute of Dermatologic Laser Surgery, it produces the largest single-session change and the longest recovery. It is a single-treatment intervention rather than a course.

  • Full-field erbium resurfacing: A 2940 nm erbium-doped yttrium aluminum garnet system at approximately 5–20 J/cm² over multiple passes, removing roughly 20–30 µm of tissue per pass with minimal residual thermal damage. It gives more precise depth control, faster healing and a lower pigmentary complication rate than carbon dioxide, at the cost of less collagen contraction; variable-pulse systems deliberately reintroduce some coagulation to recover part of that effect.

  • Ablative fractional resurfacing: The current mainstream approach, using fractional carbon dioxide or erbium delivery at 10–30 mJ per microbeam and 5–25% surface coverage, over one to three sessions spaced four to eight weeks apart. This grew directly out of the fractional photothermolysis work of Dieter Manstein and R. Rox Anderson at the Wellman Center for Photomedicine.

  • Non-ablative fractional resurfacing: A 1550 nm erbium-doped fiber or 1927 nm thulium system over four to six sessions at two- to four-week intervals, coagulating dermal columns without removing the epidermis. It is the standard route in Fitzpatrick phototypes IV–VI and where recovery time is the binding constraint.

  • Competing approaches without a default: Deep chemical peeling with phenol–croton oil, developed in its modern titrated form by Gregory Hetter, achieves comparable or greater wrinkle improvement to full-field ablative resurfacing at lower equipment cost, with a different risk profile centred on cardiac monitoring during application. Radiofrequency microneedling and microfocused ultrasound target laxity more directly than resurfacing does. Combination protocols pairing laser with radiofrequency or intense pulsed light have pooled evidence of higher improvement and satisfaction with less pain than single-device treatment. Practitioners align with one of these on the basis of training and equipment as much as on comparative data; the literature does not identify a single approach as superior across all endpoints.

  • Best time of day: Morning scheduling is standard for ablative treatment, allowing the peak oedema and oozing phase to occur during waking hours when cleansing and ointment reapplication are practical, and permitting same-day review before the first night. Non-ablative fractional sessions carry no meaningful timing constraint. Post-procedure sleep with the head elevated 30–45 degrees for the first three to five nights reduces morning oedema regardless of scheduling.

  • Dose delivery rather than dose splitting: Systemic pharmacokinetic considerations such as half-life and single-versus-divided dosing do not apply to a device-delivered intervention. The structural equivalent is whether total energy is delivered in one deep session or split across several lighter ones: split delivery achieves comparable cumulative remodelling with lower peak injury depth, while single-session delivery produces a larger immediate change and one recovery period rather than several.

  • Genetic considerations in protocol selection: Pigmentation genotype expressed through Fitzpatrick phototype is the primary determinant of device class, coverage density and pre-treatment regimen. Known keloid predisposition or a family history of hypertrophic scarring argues for non-ablative delivery, conservative density and avoidance of off-face sites. Pharmacogenetic variation is relevant only to the anaesthetic and analgesic component — notably CYP2D6 (a liver enzyme that activates codeine and metabolises several opioids), where poor metabolisers derive little analgesia from codeine.

  • Sex-based protocol adjustments: Higher fluence or an additional pass is often required in male facial skin to reach equivalent depth through a thicker dermis, and beard-bearing areas need attention to the risk of folliculitis (inflamed, infected hair follicles) during healing. In women, active or historical melasma redirects protocol toward non-ablative delivery with extended pigment-suppressing pre-treatment, and elective treatment is generally scheduled away from pregnancy and the immediate postpartum period.

  • Age-related protocol adjustments: Past roughly age 70, reduced density, longer inter-session intervals of eight to twelve weeks, and an expectation of six rather than three months to visible remodelling are standard. Anticoagulant and antiplatelet use, more prevalent in this group, requires coordination before treatment. Below age 35, resurfacing for photoaging usually has little to act on and non-ablative protocols dominate.

  • Baseline biomarker thresholds before treatment: Hemoglobin A1c, serum albumin, ferritin and 25-hydroxyvitamin D are the practical determinants of healing capacity and are corrected before elective ablative treatment where deficient. Herpes simplex serology determines the intensity of antiviral prophylaxis, though prophylaxis is given regardless of serostatus by most practitioners.

  • Pre-existing conditions affecting protocol: Diabetes, immunosuppression, prior facelift, prior radiotherapy to the field and active inflammatory skin disease each shift the protocol toward lower density, non-ablative delivery, extended prophylaxis, or deferral. Prior lower blepharoplasty with residual lid laxity requires reduced periorbital settings or exclusion of that subunit.

Discontinuation & Cycling

  • Episodic rather than lifelong: Laser resurfacing is delivered as a discrete treatment or short course, not as an ongoing therapy, so there is nothing to discontinue in the pharmacological sense. Results from full-field ablative treatment are typically described as persisting five to ten years; fractional results are shorter-lived, generally one to three years, because less tissue is remodelled per session.

  • No withdrawal effects: There is no physiological dependence, no rebound phenomenon and no withdrawal syndrome, because the intervention produces a structural change and then ends. What is sometimes described as rebound is the resumption of the normal photoaging trajectory from a younger-appearing baseline, which can read as rapid decline against the post-treatment comparison.

  • No tapering required: Tapering is not applicable. Where a planned course of fractional sessions is stopped early, the collagen response to sessions already delivered proceeds to completion over three to six months; the result is simply proportionally smaller, with no adverse consequence from stopping.

  • Maintenance rather than cycling: Efficacy is not maintained by cycling in the sense used for pharmacological agents. Practitioners typically schedule a maintenance non-ablative or light fractional session every 12–24 months, with repeat full-field ablative treatment rarely performed more than once or twice in a lifetime. A minimum interval of six to eight weeks between fractional sessions allows collagen remodelling from the prior session to complete before further injury.

  • Limits on repetition: Cumulative injury is the constraint on frequency. Repeated deep treatment at short intervals is avoided because each session must complete its remodelling phase before the next, and because of the unquantified but plausible concern that repeated aggressive treatment depletes the fibroblast and adnexal reserve the response depends on.

Sourcing and Quality

  • Device provenance and regulatory clearance: Resurfacing lasers reach the United States market through the Food and Drug Administration’s 510(k) pathway, which requires demonstration of substantial equivalence to an existing device rather than independent proof of efficacy. Established manufacturers with published clinical data include Lumenis, Solta Medical, Sciton, Candela, Cynosure and Alma. Grey-market, refurbished and imported unbranded systems are widely available and are associated with uncalibrated energy delivery, which is a direct burn and scarring hazard.

  • What to verify about the device: Whether the specific device is cleared for the intended indication, when it was last calibrated and serviced by the manufacturer, and whether the operator has manufacturer-specific training for that platform. Marketing names do not map reliably to underlying technology — several distinct wavelengths and delivery architectures are sold under similar branding — so wavelength, pulse structure and coverage density are the parameters that matter rather than the trade name.

  • Practitioner credentialling: Board certification in dermatology, plastic surgery, or facial plastic surgery with documented resurfacing volume is the relevant quality marker, since operator experience is the strongest predictor of complication rate in the published data. Regulation of delegation to nurses, physician assistants and unlicensed operators varies widely by jurisdiction, and the reported burn and scarring cases cluster in loosely supervised settings.

  • Anaesthetic and topical product quality: Compounded high-concentration topical anaesthetics are a genuine hazard when applied over a large surface area under occlusion, having caused fatal systemic lidocaine toxicity outside supervised settings; commercially manufactured formulations at labelled concentrations carry no equivalent compounding variability. Post-procedure topicals in standard aftercare protocols are limited to pharmaceutical-grade petrolatum and bland cleansers; the “post-laser recovery” product category is unregulated and its botanical ingredients are a common source of contact dermatitis through a disrupted barrier.

  • Third-party verification where it exists: Unlike supplements, there is no independent testing body certifying resurfacing devices or post-procedure topicals. The closest available substitutes are peer-reviewed clinical data on the specific platform rather than the device class, manufacturer service records, and adverse-event reporting through the Food and Drug Administration’s device reporting database, which is publicly searchable.

Practical Considerations

  • Time to effect: Surface texture and pigment improvement become apparent once re-epithelialization completes, at roughly 7–14 days for ablative and 3–7 days for non-ablative fractional treatment, though erythema masks the result initially. The collagen-mediated component — wrinkle depth and dermal thickness — accumulates over three to six months and is not fully assessable before then. Judging the outcome at one month systematically overestimates the durable effect, because oedema and epidermal thickening contribute to the early appearance.

  • Common pitfalls: The most frequent error is expecting ablative-magnitude results from a low-density non-ablative protocol chosen for its short recovery. Others include treating recently tanned skin, which sharply raises pigmentary complication risk; abandoning photoprotection once the skin looks healed, which reverses the pigmentary benefit; expecting resurfacing to correct volume-loss laxity, which is anatomically outside its reach; and selecting an operator on price in a market where complication rate tracks operator experience.

  • Regulatory status: The devices are cleared, not approved, under the Food and Drug Administration’s 510(k) pathway on the basis of equivalence to predicate devices. Specific cosmetic indications are frequently promoted beyond the cleared labelling, which is lawful as physician practice but means the marketed claim is not necessarily one the regulator has evaluated. Facility and operator regulation for energy-based devices is set at state level and varies substantially.

  • Cost and accessibility: Fractional sessions typically run roughly 1,000–3,000 US dollars each with a course of three to five required; full-field ablative treatment typically runs 3,000–8,000 US dollars as a single procedure, with anaesthesia charged separately. None of this is covered by insurance when performed for cosmetic indications, and the total for a fractional course frequently exceeds that of a single ablative treatment while producing less change.

  • Payer incentives and their effect on the evidence base: Where laser resurfacing competes with much cheaper alternatives for a covered indication — actinic keratosis, where cryotherapy and topical 5-fluorouracil cost a small fraction as much — insurers and national health systems have a clear financial incentive to favour the cheaper option, and coverage policy reflects that. That incentive shapes which comparisons get funded and which appear in treatment guidelines, so the relative absence of large independent trials of laser treatment for field damage reflects funding structure as well as scientific priority. In the purely cosmetic setting the incentive runs the other way: because no payer is involved, essentially all trial funding originates with device manufacturers and practitioner societies, whose members’ revenue depends on the procedures being performed.

  • Professional-society material and its incentives: Patient-facing guidance from bodies such as the American Society for Dermatologic Surgery is clinically accurate and useful for procedural expectations, but that organisation’s membership derives direct revenue from performing the procedures it describes, and its material both informs and markets. The same caution applies symmetrically to the societies and manufacturers advocating competing approaches such as radiofrequency and injectable treatments.

Interaction with Foundational Habits

  • Sleep: The interaction is bidirectional and short-lived. Oedema, stinging and the need for overnight occlusive ointment disrupt sleep for the first three to five nights after ablative treatment, and sleeping with the head elevated 30–45 degrees reduces morning swelling. In the other direction, slow-wave sleep is when growth hormone secretion peaks and the bulk of tissue repair occurs, so sleep restriction during the healing window measurably slows re-epithelialization. In practice, protocols place treatment where a protected sleep period is available rather than in a high-demand week.

  • Nutrition: Direct and potentiating. Collagen synthesis is substrate-limited: vitamin C is a required cofactor for the prolyl and lysyl hydroxylase enzymes that stabilise the collagen triple helix, zinc is required for the enzymes driving epithelial proliferation, and total protein intake sets the ceiling on matrix deposition. Protein intake of 1.2–1.6 g/kg body weight daily, vitamin C of 500–1,000 mg daily, and zinc of 15–30 mg daily during the healing phase are the parameters practitioners use. Alcohol is avoided for at least 48 hours before and during re-epithelialization because it impairs the inflammatory phase and worsens oedema, and a high-glycaemic diet raises advanced glycation end-products that cross-link and stiffen the very collagen the procedure is trying to rebuild.

  • Exercise: Blunting during the healing window, neutral thereafter. Strenuous exercise raises facial blood flow, prolongs erythema and produces sweat that macerates the healing field and raises infection risk, so it is suspended for five to seven days after ablative treatment, with heat exposure from saunas, hot yoga and steam avoided for two to four weeks. Light walking from 48 hours is unproblematic. Beyond that window there is no interaction, and habitual aerobic fitness is associated with better cutaneous microvascular function and faster healing.

  • Stress management: Indirect but mechanistically established. Sustained cortisol elevation suppresses the inflammatory phase of wound repair and reduces collagen deposition, and psychological stress has been shown in controlled human wounding studies to measurably delay closure. The practical considerations are two: the visible downtime is itself a stressor that is reduced by scheduling around social and work commitments rather than absorbing it into a busy period, and stress-reduction practices with evidence of cortisol effect — regular sleep timing, breathing practice, time outdoors under photoprotection — are typically maintained through the healing window rather than displaced by it.

Monitoring Protocol & Defining Success

Baseline assessment before elective resurfacing serves two purposes: confirming that healing capacity is adequate, and establishing the objective starting point against which any claimed improvement will later be judged. The laboratory panel below targets the metabolic, nutritional and inflammatory determinants of wound healing; hemoglobin A1c reflects average blood sugar over roughly three months, high-sensitivity C-reactive protein is a sensitive marker of systemic inflammation, and 25-hydroxyvitamin D is the storage form used to assess vitamin D status. Baseline standardised photography under fixed lighting, along with a documented Fitzpatrick phototype and Glogau photoaging class (a I–IV classification of wrinkle severity and sun damage), is at least as important as the bloodwork and is frequently omitted.

Ongoing monitoring follows a fixed cadence: wound review at day 3 and day 7–10 during re-epithelialization, pigmentary assessment at week 4 and week 8 when post-inflammatory hyperpigmentation peaks, outcome assessment with repeat standardised photography at month 3 and month 6 once collagen remodelling has completed, and annual review thereafter. Laboratory testing is repeated only where a baseline abnormality was being corrected or where healing is delayed.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Hemoglobin A1c 4.8–5.4% Glycemic control predicts re-epithelialization speed Conventional threshold for concern is 5.7%; elective ablative treatment usually deferred above 8.0%. No fasting required; reflects ~3 months
Fasting glucose 75–86 mg/dL Confirms current glycemic state alongside the 3-month average Conventional reference extends to 99 mg/dL. Requires 8–12 h fast; draw with hemoglobin A1c
Serum albumin 4.2–5.0 g/dL Marks protein availability for collagen matrix synthesis Conventional range starts at 3.5 g/dL, which is too low to assure healing substrate. Falls in inflammation; interpret with high-sensitivity C-reactive protein
Ferritin 50–150 ng/mL (women), 50–200 ng/mL (men) Iron is a cofactor for the enzymes that stabilise collagen Conventional lower limit of 15–30 ng/mL is far below the functional target. Acute-phase reactant; pair with high-sensitivity C-reactive protein and transferrin saturation
25-hydroxyvitamin D 40–60 ng/mL Supports keratinocyte differentiation and barrier recovery Conventional sufficiency is ≥30 ng/mL. Not fasting-dependent; correction takes 8–12 weeks, so test early
High-sensitivity C-reactive protein <0.5 mg/L Pro-inflammatory baseline predicts prolonged post-procedure erythema Conventional low-risk cut-off is <1.0 mg/L and general reference <3.0 mg/L. Invalid within 2 weeks of infection or injury
Serum zinc 90–120 µg/dL Required for epithelial proliferation and wound closure Conventional reference starts near 60 µg/dL, well below the functional target. Morning fasting draw; withhold zinc supplements 24 h prior. Pair with copper if supplementing long-term
Complete blood count with differential Hemoglobin 13.5–15.0 g/dL (women), 14.5–16.5 g/dL (men) Oxygen delivery to the healing field; screens for occult infection risk Conventional ranges extend lower. Fasting not required
Herpes simplex virus type 1 and 2 IgG antibodies Negative preferred; positive is not a contraindication Identifies latent infection that resurfacing can reactivate IgG is immunoglobulin G, the long-lasting antibody class that marks past exposure. Most practitioners give antiviral prophylaxis regardless of result. One-time test; no fasting
Plasma ascorbate (vitamin C) 0.8–1.5 mg/dL Rate-limiting cofactor for collagen cross-linking Conventional reference extends down to roughly 0.2–0.4 mg/dL, far below the functional target. Rarely ordered but informative in restricted diets or smokers. Fasting morning draw; sample is light-sensitive and degrades quickly

Qualitative and functional markers matter more than laboratory values for defining success, since the endpoint is visible and structural:

  • Standardised photography under fixed lighting and positioning at baseline, month 3 and month 6 — the only defence against recall bias, which is substantial for appearance outcomes
  • Fitzpatrick wrinkle severity and Glogau photoaging class scored by the same assessor at baseline and month 6
  • Time to complete re-epithelialization relative to the expected 10–21 days, as an early signal of impaired healing
  • Trajectory of erythema resolution week by week, with any increase after initial improvement suggesting infection or contact dermatitis rather than normal healing
  • Onset of pigmentary change at weeks 4–8, the window in which post-inflammatory hyperpigmentation appears
  • Self-assessed skin texture, makeup requirement and confidence in appearance, captured with a validated instrument such as the FACE-Q appearance appraisal scales rather than open-ended recollection
  • Sleep quality and daily function during the recovery period, which determine whether a repeat treatment is realistic

Emerging Research

Emerging work is presented here for a reader deciding whether to act now or wait, so it includes both the studies that could raise confidence in resurfacing and those that could reduce it.

  • Head-to-head long-pulsed neodymium-doped yttrium aluminum garnet versus fractional carbon dioxide: NCT07467954, recruiting at Universitas Padjadjaran with 15 participants, compares a 1064 nm long-pulsed system against fractional carbon dioxide with dermal thickness, skin elasticity and wrinkle scores as primary endpoints. Its value is the use of instrumented dermal measurement rather than observer rating alone, though the sample size limits it to hypothesis generation.

  • Laser-assisted delivery of topical actives: NCT07376148, a phase 4 study of 30 participants over age 30 at the Instituto de Oftalmología Fundación Conde de Valenciana, tests fractional carbon dioxide-assisted delivery of hyaluronic acid, ascorbic acid and sodium DNA with facial skin quality as the primary endpoint. This addresses the open question of whether laser-assisted delivery adds measurable benefit over resurfacing alone in a purely cosmetic setting.

  • Next-generation 2910 nm erbium-doped fluoride fiber lasers: NCT07222397, recruiting 20 participants for advanced perioral lines, and NCT07254884, a 40-participant study of resurfacing plus laser coring for rhytids and skin laxity. Both are sponsored by FA Corporation, the device manufacturer, which is the standard funding pattern in this field and means the comparators, endpoints and settings are chosen by the party with a commercial interest in the result.

  • Combination energy-based protocols: NCT07107308, 25 participants at the Second Affiliated Hospital of Xi’an Jiaotong University, evaluates microfocused ultrasound combined with a 1550 nm non-ablative fractional laser for facial rejuvenation. It tests directly whether the combination advantage reported in pooled trial data holds when laxity and resurfacing devices are paired.

  • Large device-registry evidence: NCT06868615, a 200-participant study sponsored by AVAVA, Inc. covering wrinkles, pigmented lesions, scars and texture. Its size is unusual for this field, but the primary endpoint is completion of a post-treatment subject questionnaire rather than an objective outcome, which limits what it can establish about efficacy.

  • Laser-based skin cancer prevention: The evolving landscape of laser-based skin cancer prevention (Wenande et al., 2025) maps the current state of the hypothesis that resurfacing lowers subsequent keratinocyte carcinoma incidence. If prospective work confirms it, resurfacing moves from a cosmetic procedure to a preventive one, which would substantially change the risk-benefit calculation for anyone with significant sun damage.

  • Resurfacing combined with facelift surgery: Laser Resurfacing at the Time of Facelift Surgery: A Systematic Review and Meta-Analysis (Wen et al., 2026) pools the evidence on simultaneous resurfacing and rhytidectomy, a combination long avoided over flap-perfusion concerns. It addresses whether the two can be safely combined in one recovery period.

  • Direct comparison against chemical peeling: Comparative Efficacy and Safety of Laser versus Chemical Skin Peeling in Skin Rejuvenation: A Systematic Review and Meta-Analysis (Karanasios et al., 2026) is among the studies most likely to weaken the case for laser resurfacing, since deep chemical peeling achieves comparable wrinkle improvement at a fraction of the equipment cost. A finding of equivalence would reframe device expenditure as the main differentiator.

  • Structural weaknesses that future work could expose: No randomized trial of resurfacing for rejuvenation has followed participants beyond about two years, so the widely repeated durability figures rest on uncontrolled follow-up. Nearly all efficacy endpoints are investigator-rated ordinal scales, which pooled analyses such as Sodagar et al., 2025 and Seirafianpour et al., 2022 inherit and cannot correct. Adequately powered independent trials comparing full-field ablative against fractional delivery have never been run, and the trials that exist are small enough that the pooled confidence intervals (the ranges within which the true effect plausibly lies) remain compatible with both a large benefit and none.

Conclusion

Laser resurfacing uses focused light to remove or heat the outer and middle layers of skin, prompting the body to rebuild them with newer, better-organised connective tissue. The most consistent evidence supports visible reduction of facial lines, more even colour, and smoother texture, together with improvement of sunken acne marks. Deeper treatments covering the whole surface produce the largest changes; the gentler versions treating only part of the surface, which most clinics now favour, trade some of that effect for shorter recovery. Improvement in sagging is smaller, and the evidence there conflicts.

Redness, swelling and peeling follow every effective treatment and can persist for weeks to months after the deepest versions. Darker skin tones carry a meaningfully higher chance of temporary darkening, and the deepest treatments carry a small but permanent risk of lightening and of scarring. Cold-sore reactivation and infection are largely preventable with medication and careful aftercare.

The evidence base is thin in a specific way: most trials are small, short, judged by eye rather than by instrument, and funded or conducted by the device makers and the practitioner societies whose members are paid to perform the procedure. That does not make the findings wrong, but the size and durability of the benefit are less certain than the volume of published work suggests. For someone weighing a one-time intervention with a visible outcome and a recovery period that can be planned around, the treatment consistently produces a change, while the size of that change remains loosely defined.

Top - Benefits - Risks - Protocol